OBJECTIVES: To estimate the annual impact of the inclusion of nonacog beta pegol in the Colombian health system for the prophylaxis treatment of previously treated patients with a confirmed diagnosis of haemophilia B.

METHODS: An Excel BIA model was built to estimate the economic impact of the progressive inclusion of nonacog beta pegol in the Colombian institutional health market for the prophylactic treatment of haemophilia B. The model was developed and populated with local data from The National Administrative Department of Statistics (DANE) and epidemiological data from the public and official records of the High-Cost Account (CAC) of 113 patients with haemophilia B in 2021; Clinical information including dosage, treatment schemes and annual bleeding rates were obtained from the published clinical trial of nanocog beta pegol and nonacog alfa. The costs were calculated and expressed in US dollars (USD) for a 3-year horizon, according to the Medicine Price Information System (SISMED) and the fee manual of a private hospital. A deterministic sensitivity analysis was implemented.

RESULTS: The BIA showed that the inclusion of nonacog beta pegol resulted in savings of USD $604,842, USD $582,607 and USD $561,154 for the first, second and third year, respectively. As a complementary analysis, the number of additional potential patients that could be treated per year due to savings was calculated: year1: 5 patients; year2: 4.8 patients and year3: 4.6 patients.

CONCLUSIONS: The inclusion of nonacog beta pegol in the Colombian health system for the treatment of patients with haemophilia B in prophylaxis can result in savings of up to USD1,748,603 over a 3-year horizon.